• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Roche Terminates Cancer Treatment Pact With Blueprint Medicines


Roche Holdings AG has decided to terminate its collaboration agreement with Blueprint Medicines Corporation for strategic reasons, allowing Blueprint Medicines to regain global commercialization and development rights to Gavreto (pralsetinib), except in Greater China. The termination will be effective in 12 months. Blueprint Medicines plans to explore options to advance and simplify the continued global commercialization and development of Gavreto, which was approved by the FDA for three indications in lung and thyroid cancer settings. The company anticipates no impact on its 2023 revenue guidance and expects its current cash position and future product revenues to enable it to achieve a self-sustainable financial profile.

Recent Videos
Related Content